206 related articles for article (PubMed ID: 34346071)
1. Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
Mikhailova E; Roumiantseva J; Illarionova O; Lagoyko S; Miakova N; Zerkalenkova E; Zharikova L; Olshanskaya Y; Novichkova G; Maschan M; Henze G; Karachunskiy A; Popov A
Br J Haematol; 2022 Jan; 196(1):e6-e9. PubMed ID: 34346071
[No Abstract] [Full Text] [Related]
2. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
3. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
5. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
6. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
[No Abstract] [Full Text] [Related]
7. Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
Liu Z; Li Y; Shi C
Int J Hematol; 2021 Mar; 113(3):337-343. PubMed ID: 33502735
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of blinatumomab: a real world data.
Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
[TBL] [Abstract][Full Text] [Related]
9. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
[TBL] [Abstract][Full Text] [Related]
10. A closer look at blinatumomab.
Mattison RJ
Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
[TBL] [Abstract][Full Text] [Related]
11. Durable remissions in
Mouttet B; Vinti L; Ancliff P; Bodmer N; Brethon B; Cario G; Chen-Santel C; Elitzur S; Hazar V; Kunz J; Möricke A; Stein J; Vora A; Yaman Y; Schrappe M; Anak S; Baruche A; Locatelli F; von Stackelberg A; Stanulla M; Bourquin JP
Haematologica; 2019 Jun; 104(6):e244-e247. PubMed ID: 30765470
[No Abstract] [Full Text] [Related]
12. Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).
Sakaguchi H; Umeda K; Kato I; Sakaguchi K; Hiramatsu H; Ishida H; Yabe H; Goto H; Kawahara Y; Yamashita YI; Sanada M; Deguchi T; Takahashi Y; Saito A; Noma H; Horibe K; Taga T; Adachi S;
BMJ Open; 2023 Apr; 13(4):e070051. PubMed ID: 37068890
[TBL] [Abstract][Full Text] [Related]
13. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
14. Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy.
Balducci E; Nivaggioni V; Boudjarane J; Bouriche L; Rahal I; Bernot D; Alazard E; Duployez N; Grardel N; Arnoux I; Lafage-Pochitaloff M; Michel G; Nadel B; Loosveld M
Ann Hematol; 2017 Sep; 96(9):1579-1581. PubMed ID: 28634616
[No Abstract] [Full Text] [Related]
15. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
16. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
17. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P
Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608
[TBL] [Abstract][Full Text] [Related]
18. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement.
Zoghbi A; Zur Stadt U; Winkler B; Müller I; Escherich G
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28453885
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antibodies in acute lymphoblastic leukemia therapy.
Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
